For the first time in more than fifty years, the federal government is preparing to treat marijuana as something other than a substance with no accepted medical use. In April, the Department of Justice and the Drug Enforcement Administration proposed rescheduling state-licensed medical cannabis and FDA-approved marijuana products from Schedule I to Schedule III under the Controlled Substances Act - a classification shift that carries real consequences for research, taxation, and the millions of Americans who rely on cannabis medically. Gretchen Gailey, President of Project Champion and a longtime medical cannabis advocate, has been watching this process closely, and her perspective carries weight: she has worked with patients and policymakers through years of stalled federal reform.
What Schedule III Actually Means
Schedule I, where cannabis has sat since 1970, designates a substance as having high abuse potential and no accepted medical application - the same category as heroin. That classification has never accurately described how physicians, researchers, or patients have engaged with cannabis, but it has dictated everything from research access to how dispensaries file their taxes. Schedule III is a different world. It includes substances like ketamine and certain anabolic steroids - drugs that carry some abuse potential but also recognized therapeutic value.
The practical downstream effects of rescheduling are significant, even if not total. State-licensed medical cannabis businesses currently cannot deduct standard business expenses under federal tax code Section 280E, which applies to traffickers of Schedule I and II substances. Rescheduling to Schedule III would remove that restriction - a financial relief that, for many operators, represents the difference between solvency and collapse. Research barriers, long the most frustrating consequence of Schedule I status, would also ease: academic institutions and pharmaceutical researchers would face fewer DEA licensing hurdles to study cannabis compounds.
Here's the catch, though. Rescheduling is not legalization. Interstate commerce in cannabis would remain a federal offense. State-licensed dispensaries would still exist in a complicated legal gray zone relative to federal law. And the rulemaking process - still ongoing as of this writing - includes a formal comment period and potential administrative law proceedings, meaning the final rule is not yet in effect.
A Decades-Long Push Reaches an Inflection Point
The road here was not short. Cannabis was placed in Schedule I provisionally in 1970, pending review by the Shafer Commission - which then recommended decriminalization. That recommendation was rejected. Subsequent petitions to reschedule, filed by advocates and researchers over the following decades, were denied repeatedly. What changed the calculus, more than any single event, was the accumulation of state-level medical programs: as of now, the majority of states have enacted some form of medical cannabis access, creating a political and public health reality that federal classification could no longer credibly ignore.
Advocates like Gailey have been part of that long arc - making the case not in abstractions but in patient outcomes, in the documented relief that cannabis has provided for conditions ranging from chronic pain to chemotherapy-induced nausea to certain seizure disorders. Project Champion's work reflects that patient-centered framing, which has proven more durable in policy conversations than purely libertarian or commercial arguments.
What Comes Next, and What Remains Unresolved
The DEA's proposed rule still has to clear the administrative process. A DEA administrative law judge could hold hearings; the comment record will be reviewed; the final rule could look different from the proposal. And Congress retains the authority to act independently - some legislators have pushed for more comprehensive reform, arguing that rescheduling alone does not resolve the fundamental conflict between state and federal law.
For patients, the most immediate question is practical: will rescheduling translate into better access, more research, and - eventually - insurance coverage for cannabis-based treatments? None of that is guaranteed by a classification change alone. But the signal it sends matters. Federal agencies operate in part on precedent and stated policy direction. A Schedule III designation would, at minimum, stop the federal government from actively contradicting the medical consensus that has been building for decades.
To put it plainly: this is not the end of cannabis prohibition, and it was never meant to be. What it represents is a federal acknowledgment - formal, rulebound, and imperfect - that the Schedule I designation was no longer defensible as a description of medical reality. For advocates who have spent years making that argument, that acknowledgment is not nothing.
